<ARTICLE> 5 <MULTIPLIER> 1 <PERIOD-TYPE> 3-MOS <FISCAL-YEAR-END> DEC-31-1996 <PERIOD-END> MAR-31-1996 <CASH> 23,102,528 <SECURITIES> 3,152,481 <RECEIVABLES> 413,984 <ALLOWANCES> 0 <INVENTORY> 367,977 <CURRENT-ASSETS> 28,968,004 <PP&E> 7,491,141 <DEPRECIATION> 843,875 <TOTAL-ASSETS> 35,681,952 <CURRENT-LIABILITIES> 10,633,633 <BONDS> 0 <PREFERRED-MANDATORY> 124,260 <PREFERRED> 0 <COMMON> 0 <OTHER-SE> 24,274,724 <TOTAL-LIABILITY-AND-EQUITY> 35,681,952 <SALES> 0 <TOTAL-REVENUES> 1,265,855 <CGS> 0 <TOTAL-COSTS> 3,749,647<F1> <OTHER-EXPENSES> 0<F1> <LOSS-PROVISION> 0 <INTEREST-EXPENSE> (130,033) <INCOME-PRETAX> (2,981,681) <INCOME-TAX> 14,740 <INCOME-CONTINUING> (2,996,421) <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> (2,996,421) <EPS-PRIMARY> (0.28) <EPS-DILUTED> (0.28) <FN> <F1>Total costs includes research and development expenses and cost of revenues. Because of the natur of the Company's operations, management is of the opinion that it is not meaningful to segregate these costs </FN>